Migraine prevention gets its first update in 14 years

Migraine is a neurological condition that goes well beyond severe headache. Attacks can involve nausea, sensitivity to light and sound, and sometimes visual disturbances called auras. Chronic migraine, defined as more than fifteen attacks per month, can substantially reduce quality of life. Long-term, unmanaged migraine is also associated with increased risk of stroke and cognitive decline in later life.

The new guidelines, released by the American Headache Society and the American Academy of Neurology, reflect a much wider range of treatment options than were available in 2012. Chief among these are drugs that target the CGRP system, a signalling pathway in the brain involved in transmitting pain during migraine attacks.

What has changed in treatment

CGRP inhibitors are available as injections or pills and work directly on the mechanism that triggers attacks. For some patients they outperform older preventive drugs such as beta-blockers or anticonvulsants. The updated guidelines give clinicians a structured framework for matching the right drug to the right patient profile.

From a longevity perspective, migraine is relevant for a reason that often goes unnoticed: repeated severe attacks are associated with small brain lesions and a higher risk of vascular decline. Preventing migraine is therefore not only about pain relief but potentially also about preserving long-term brain health.

Guidelines as a practical tool

Guidelines are not mandates, but they give clinicians an evidence-based starting point. With the previous guidelines fourteen years out of date, many newer options were underused in practice. The update is primarily a practical improvement in day-to-day care rather than a scientific breakthrough in itself.

Read the original article